|
|
|
| Efficacy of Combined Treatment with Metformin, Englitazone, Polyethylene Glycol Loxenatide, and Exercise Therapy in Patients with Obese Type 2 Diabetes |
| LI Pengyang, DU Xin, CHEN Changlong |
| Departments of Internal Three,the First People's Hospital of Wancheng District, Nanyang City, Henan Province, Nanyang Henan 473001 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of a combination treatment of metformin, empagliflozin, pegylated liraglutide and exercise therapy in the treatment of obese type 2 diabetes. 【Methods】A total of 112 obese type 2 diabetes patients admitted to our hospital from October 2020 to October 2023 were selected and divided into groups by the ball-picking method (odd numbers assigned to the control group and even numbers to the observation group), with 56 cases in each group. The control group was treated with metformin, empagliflozin combined with exercise therapy, while the observation group was treated with pegylated liraglutide in addition to treatment of the control group. The glycolipid metabolism indicators, pancreatic β-cell function, and carotid atherosclerosis indicators were compared before and after treatment in both groups. 【Results】After treatment, the levels of fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group, while the level of high-density lipoprotein cholesterol (HDL-C) was higher than that in the control group, and the differences were statistically significant (P<0.05). The pancreatic β-cell function index (HOMA-β) in the observation group was higher than that in the control group, and the insulin resistance index (HOMA-IR) was lower than that in the control group, and the differences were statistically significant (P<0.05). The carotid intima-media thickness (CIMT) and pulse wave velocity (PWV) in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】The combination of metformin, empagliflozin, pegylated liraglutide and exercise therapy in the treatment of obese type 2 diabetes patients can significantly improve glycolipid metabolism, enhance pancreatic β-cell function, and reduce atherosclerosis indicators.
|
|
Received: 18 July 2024
|
|
|
|
|
|
[1] 李芝,李堃宜,钟志鹏,等. 聚乙二醇洛塞那肽联合达格列净治疗肥胖2型糖尿病患者的疗效及安全性研究[J].中国医院药学杂志,2021,41(9):936-939.
[2] 梁斌,李兰,魏东. 聚乙二醇洛塞那肽联合二甲双胍对2型糖尿病患者的临床疗效[J].川北医学院学报,2021,36(2):246-249.
[3] 姚璐,武云涛,田国祥,等. 聚乙二醇洛塞那肽注射液联合二甲双胍对2型糖尿病患者的疗效[J].中国循证心血管医学杂志,2017,9(5):577-579.
[4] 李良浩,常颖,郑艺荣. 卡格列净联合洛塞那肽对2型糖尿病胰岛素抵抗患者胰岛功能、YKL-40、PPARγ的影响[J].中南医学科学杂志,2024,52(1):120-122.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[6] 赵永强,秦晓利,田德增. 聚乙二醇洛塞那肽注射液联合二甲双胍片治疗肥胖2型糖尿病的效果及对血清抗氧化因子、炎性因子的影响[J].中国药物滥用防治杂志,2022,28(1):77-81.
[7] 张梦瑶,牛姝,张弛,等. 聚乙二醇洛塞那肽注射液(PEX168)联合胰岛素对2型糖尿病合并骨质疏松患者糖代谢、骨代谢的影响[J].河北医药,2022,44(12):1822-1825.
[8] 王启生,孟晓萍,柴月星,等. 达格列净联合洛塞那肽治疗2型糖尿病胰岛素抵抗患者的疗效及对糖脂代谢、β细胞功能的影响[J].中国医师杂志,2023,25(6):928-931.
[9] 马博乐,赵振宇. 基于Markov模型的聚乙二醇洛塞那肽与二甲双胍联合治疗2型糖尿病的药物经济学评价[J].中国医院药学杂志,2023,43(19):2194-2197.
[10] 马静,李福旺,邵爽,等. 消渴康颗粒联合洛塞那肽治疗2型糖尿病的临床研究[J].现代药物与临床,2022,37(9):2064-2068.
[11] 田雄涛,刘立栋,刘晓宇. 聚乙二醇洛塞那肽注射液联合二甲双胍对初诊肥胖2型糖尿病的疗效及安全性评价[J].中国药物与临床,2022,22(3):197-200.
[12] 谷敬锋,刘海霞,冯峰,等. 聚乙二醇洛塞那肽治疗肥胖型2型糖尿病患者轴状胃切除术患者的临床研究[J].中国临床药理学杂志,2024,40(3):330-334.
[13] 叶启宝,陈望,李颖,等. 达格列净联合聚乙二醇洛塞那肽治疗超重/肥胖2型糖尿病患者的有效性及安全性研究[J].医学研究杂志,2023,52(2):114-118.
[14] 王燕,张秀娟. 聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积的影响[J].山东医药,2022,62(25):35-38.
[15] 周英旎,石敏,赖敬波,等. 聚乙二醇洛塞那肽联合二甲双胍治疗新诊断肥胖2型糖尿病[J].实用医学杂志,2023,39(2):170-174. |
|
|
|
2025, Vol. 42 
